Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06130631
Other study ID # Steroid in nephrotic syndrome
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 3, 2023
Est. completion date May 31, 2025

Study information

Verified date November 2023
Source Assiut University
Contact Maha Radwan Zaki, Doctor
Phone 01090963814
Email mahamai071@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective study of predictors of steroid response in childhood nephrotic syndrom


Description:

Nephrotic syndrome is the most common glomerular disease affecting children worldwide ,Nephrotic syndrome is the combination of nephrotic-range proteinuria with a low serum albumin level and edema. Nephrotic-range proteinuria is the loss of 3 grams or more per day of protein into the urine or, on a single spot urine collection, the presence of 2 g of protein per gram of urine creatinine. Minimal change disease (MCD) or minimal change glomerulonephritis and focal segmental glomerulosclerosis (FSGS) are the two major causes of nephrotic syndrome in children and young adults, Idiopathic, hereditary, and secondary forms are due to underlying increased protein leakiness across the glomerular capillary wall, as a result of immune and non-immune insults affecting the podocyte. The incidence worldwide varies widely between 1.2 and 16.9 cases per 100,000 children with the highest incidence observed on the Indian subcontinent compared to 2-3 cases per 100,000 children in most other regions . Males appear to be more affected than females at a ratio of 2:1 at a younger age, but this predominance fails to persist in adolescence. treatment of nephrotic syndrome:- Corticosteroids have been used to treat childhood nephrotic syndrome since 1950 when large doses of adrenocorticotrophic hormone (ACTH) and cortisone given for two to three weeks were found to induce diuresis with loss of oedema and proteinuria. The response to treatment with steroids has been shown to vary by ethnicity, likely due to environmental and genetic factors. Corticosteroid usage has reduced the mortality rate in childhood nephrotic syndrome to around 3%, with infection remaining the most important cause of death. Of children who present with their first episode of nephrotic syndrome, approximately 80% will achieve remission with corticosteroid Prednisolone is the mainstay treatment, whose response is often presumed to determine the long-term risk of disease progression and is a better prognostic indicator . Although patients with steroid-sensitive nephrotic syndrome generally have good outcomes, more than half will have a frequently relapsing course and steroid dependence. Up to 95% of patients with minimal change nephrotic syndrome (MCNS) attain complete remission after an 8-week course of high dose steroids there are some factors affecting response to treatment with the steroids such as age of onset (the older the age of onset the better the response) ,gender (the females respond more to treatment) and type of nephrotic syndrome( minimal change glomerulonephritis responds more than focal segmental glomerulosclerosis to steroids ).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 79
Est. completion date May 31, 2025
Est. primary completion date December 21, 2024
Accepts healthy volunteers
Gender All
Age group 12 Months to 18 Years
Eligibility Inclusion Criteria: - all children from 1 year to 18 years treated with steroid for nephrotic syndrom Exclusion Criteria: - children with other kideny disease Children less than 1 year old Children with secondary nephrotic syndrom

Study Design


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Maha Radwan Assiut University

References & Publications (2)

Anochie I, Eke F, Okpere A. Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc. 2006 Dec;98(12):1977-81. — View Citation

Sinha A, Bagga A. Nephrotic syndrome. Indian J Pediatr. 2012 Aug;79(8):1045-55. doi: 10.1007/s12098-012-0776-y. Epub 2012 May 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Predictors of steroid response in childhood nephrotic syndrom Retrospective study of predictors of steroid response in childhood nephrotic syndrom Sach as hypertension, hematuria,raised renal chemistry in pediatric nephrology unit and outpatient outpatient nephrology clinic at assiut university children hospital 2year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05044169 - Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome N/A
Recruiting NCT05583942 - A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) N/A
Recruiting NCT05588063 - taVNS for FRNS in Children N/A
Recruiting NCT06125405 - Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome Phase 3
Completed NCT04034316 - Reduce Immunosuppression With Atmp in NS ChildrEn Phase 2
Completed NCT04048161 - Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome Phase 4
Recruiting NCT06079788 - Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized,Open-label Clinical Trial. Phase 3
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Recruiting NCT06417320 - Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years Phase 4
Recruiting NCT05843968 - Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome Phase 2
Recruiting NCT05734794 - Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial Phase 3
Terminated NCT03878914 - Steroid Sensitive Nephrotic Syndrome in Children Phase 4
Recruiting NCT03786263 - CHILDNEPH The Canadian Childhood Nephrotic Syndrome Study
Recruiting NCT05772871 - The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children Phase 4
Recruiting NCT05505500 - Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.